References
- Chalasani N, Björnsson E. 2010. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 138:2246–2259.
- Cho T, Uetrecht J. 2017. How reactive metabolites induce an immune response that sometimes leads to an idiosyncratic drug reaction. Chem Res Toxicol. 30:295–314.
- Church R, Watkins P. 2017. The transformation in biomarker detection and management of drug-induced liver injury. Liver Intl. 37:1582–1590.
- Holman N, Mosedale M, Wolf K, LeCluyse E, Watkins P. 2016. Subtoxic alterations in hepatocyte-derived exosomes: An early step in drug-induced liver injury? Toxicol Sci. 151:365–375.
- Jansen P. 2004. Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 16:1079–1085.
- Kato R, Uetrecht J. 2017. Supernatant from hepatocyte cultures with drugs that cause idiosyncratic liver injury activates macrophage inflammasomes. Chem Res Toxicol. 30:1327–1332.
- Machado M, Michelotti G, Xie G, de Almeida T, Boursier J, Bohnic B, Guy C, Diehl A. 2015. Mouse models of diet-induced non-alcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One 10:e0127991.
- Mak A, Uetrecht J. 2015. The role of CD8 T-cells in amodiaquine-induced liver injury in PD1−/− mice co-treated with anti-CTLA-4. Chem Res Toxicol. 28:1567–1573.
- Mak A, Uetrecht J. 2017. Immune mechanisms of idiosyncratic drug-induced liver injury. J Clin Transl Res. 3:145–156.
- Mak A, Johnston A, Uetrecht J. 2017. Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury. J Immunotoxicol. 14:9–94.
- Mak A, Kato R, Weston K, Hayes A, Uetrecht J. 2017. An impaired immune tolerance animal model distinguishes the potential of troglitazone/pioglitazone and tolcapone/entacapone to cause IDILI. Toxicol Sci. 161:412–420.
- Massart J, Begriche K, Moreau C, Fromenty B. 2017. Role of non-alcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 3:212–232.
- Metushi I, Cai P, Dervovic D, Liu F, Lobach A, Nakagawa T, Uetrecht J. 2015. Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset. J Immunotoxicol. 12:247–260.
- Metushi I, Hayes M, Uetrecht J. 2015. Treatment of PD-1−/− mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. Hepatology 61:1332–1342.
- Neuberger J. 1990. Halothane and hepatitis. Incidence, predisposing factors and exposure guidelines. Drug Saf. 5:28–38.
- Russo M, Watkins P. 2004. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 126:1477–1480.
- Tarantino G, Conca P, Basile V, Gentile A, Capone D, Polichetti G, Leo E. 2007. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res. 37:410–415.
- Zimmerman H, editor. 1999. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia: Lippincott Williams & Wilkins.